anti-Colorectal Carcinoma/CD3 antibody [BS-1]

Arigo Biolaboratories

anti-Colorectal Carcinoma/CD3 antibody [BS-1]

23

Flow Cytometry, ELISA

Research Use Only

Monoclonal

BS-1

1 mg/ml

Unconjugated

Mouse

IgG1, IgG2a

Colorectal carcinoma is the cancer developed in the colon or rectum of the digestive system. In developed countries, it is the most common cancer in aging population. Genetic deposition and a less active life style contribute to the development of the cancer. Molecular pathological study showed that altered Wnt-APC-beta-catenim signaling pathway, mutated p53, and deactivated TGF-beta and DCC (Deleted in Colon Cancer) are involved with the pathogenesis. The cancer is currently screened with a fecal occult blood test in people over 50 years old and the malignancy is confirmed by tumor biopsy. The search for specific biomarker for non-invasive test is still ongoing. CD3 exists on the cell surface of all T-cell types. It is used for differentiating T-cells from other leukocytes such as B cells and natural killer cells. CD3 is the accessory molecule in the T cell receptor complex. In the presence of CD3 and aeta-chain, T-cell receptor binds to antigen presented by MHC and transfers signal for T-cell activation. The hybrid bi-specific antibody binds to CD3 and colorectal carcinoma related antigen at its two different Fabs. Theoretically, the bi-specific antibody brings the target cancer antigen near T-cells and could enhance T-cell mediated immunity to cancer. However, if the binding to CD3 disrupts the CD3s accessory function, T-cell immunity suppression could be resulted.

Human

-20°C

12352203